KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Royalty Pharma (RPRX) over the last 7 years, with Q1 2025 value amounting to $13.4 million.

  • Royalty Pharma's Gains from Investment Securities changed 0.0% to $13.4 million in Q1 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 2557.78%. This contributed to the annual value of $18.0 million for FY2024, which is 437.23% down from last year.
  • Latest data reveals that Royalty Pharma reported Gains from Investment Securities of $13.4 million as of Q1 2025, which was down 0.0% from $4.6 million recorded in Q2 2024.
  • Royalty Pharma's Gains from Investment Securities' 5-year high stood at $20.7 million during Q1 2022, with a 5-year trough of $313000.0 in Q3 2023.
  • Moreover, its 5-year median value for Gains from Investment Securities was $6.4 million (2021), whereas its average is $8.9 million.
  • As far as peak fluctuations go, Royalty Pharma's Gains from Investment Securities plummeted by 9461.64% in 2023, and later surged by 10526.08% in 2024.
  • Over the past 5 years, Royalty Pharma's Gains from Investment Securities (Quarter) stood at $6.5 million in 2021, then dropped by 10.85% to $5.8 million in 2022, then crashed by 94.63% to $313000.0 in 2023, then soared by 1370.93% to $4.6 million in 2024, then surged by 190.96% to $13.4 million in 2025.
  • Its Gains from Investment Securities was $13.4 million in Q1 2025, compared to $4.6 million in Q2 2024 and $13.4 million in Q1 2024.